POLICY: Oncology – Levoleucovorin Products

- Fusilev® (levoleucovorin injection for intravenous use – Spectrum Pharmaceuticals)
- Khapzory™ (levoleucovorin injection for intravenous use – Spectrum Pharmaceuticals)
- Levoleucovorin injection for intravenous use – various manufacturers

APPROVAL DATE: 06/18/2019

OVERVIEW
Levoleucovorin (Fusilev, Khapzory, generics) is the pharmacologically active, levo-isomer of racemic d,l-leucovorin. Levoleucovorin is a chemically reduced derivative of folic acid, which can counteract the toxic and therapeutic effects of folic acid antagonists, such as methotrexate. In addition, levoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in oncology.

Levoleucovorin is indicated:
- For rescue after high-dose methotrexate therapy in osteosarcoma, and
- To diminish the toxicity and counteract the effects of impaired methotrexate elimination and if inadvertent overdosage of folic acid antagonists, and
- For use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.¹

Guidelines

POLICY STATEMENT
Prior authorization is recommended for medical benefit coverage of levoleucovorin. Approval is recommended for those who meet the Criteria and Dosing for the listed indication(s). Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days.

Because of the specialized skills required for evaluation and diagnosis of patients treated with levoleucovorin as well as the monitoring required for adverse events and long-term efficacy, approval requires levoleucovorin to be prescribed by or in consultation with a physician who specializes in the condition being treated.
RECOMMENDED AUTHORIZATION CRITERIA
Coverage of levoleucovorin is recommended in those who meet the following criteria:

FDA-Approved Indications

1. **Osteosarcoma.** Approve for 1 year if the patient meets the following criteria (A and B):
   
   A) Levoleucovorin is used in combination with high-dose methotrexate; AND
   
   B) Levoleucovorin is prescribed by or in consultation with an oncologist.

   **Dosing.** Approve one of the following dosing regimens (A or B):
   
   A) Administer up to 7.5 mg intravenously no more frequently than once every 6 hours; OR
   
   B) Administer up to 75 mg intravenously no more frequently once every 3 hours.¹

   Note: The higher dose and more frequent administration is utilized in patients with delayed early methotrexate elimination and/or evidence of acute renal injury. The dose and/or duration of levoleucovorin therapy can be titrated up or down depending on the methotrexate level and the presence of significant clinical toxicity. Dosing with levoleucovorin is continued for 10 doses or until the methotrexate level is < 0.05 micromolar.

2. **Colon or Rectal Carcinoma.** Approve for 1 year if the patient meets the following criteria (A and B):
   
   A) Levoleucovorin is used in combination with fluorouracil-based chemotherapy; AND
   
   B) Levoleucovorin is prescribed by or in consultation with an oncologist.

   **Dosing.** Approve up to 100 mg/m² administered intravenously before each dose of 5-fluorouracil.¹

3. **Methotrexate Overdosage, Inadvertent, or Impaired Methotrexate Elimination.** Approve for 1 month.

   **Dosing.** Approve one of the following dosing regimens (A or B):
   
   A) Administer up to 7.5 mg intravenously no more frequently than once every 6 hours; OR
   
   B) Administer up to 75 mg intravenously no more frequently once every 3 hours.¹

   Note: The higher dose and more frequent administration is utilized in patients with a methotrexate level > 5 x 10⁻⁶ M at 24 hours or > 9 x 10⁻⁷ M at 48 hours, or in patients with a ≥ 50% increase in serum creatinine compared to baseline after 24 hours. The dose and/or duration of levoleucovorin therapy can be titrated up or down depending on the methotrexate level and the presence of significant clinical toxicity. Dosing with levoleucovorin is continued until the methotrexate level is < 0.05 micromolar (5 x 10⁻⁸ M).

Other Uses with Supportive Evidence

4. **Cancer Diagnosis Currently Being Treated With Methotrexate.** (Note: Examples include T-cell lymphoma, B-cell lymphoma, gestational trophoblastic neoplasm, central nervous system cancer). Approve for 1 year if levoleucovorin is prescribed by or in consultation with an oncologist.

   **Dosing.** Approve one of the following dosing regimens (A or B):
A) Administer up to 7.5 mg intravenously no more frequently than once every 6 hours; OR
B) Administer up to 75 mg intravenously no more frequently once every 3 hours.¹

Note: The higher dose and more frequent administration is utilized in patients with delayed early methotrexate elimination and/or evidence of acute renal injury. The dose and/or duration of levoleucovorin therapy can be titrated up or down depending on the methotrexate level and the presence of significant clinical toxicity. Dosing with levoleucovorin is continued for 10 doses or until the methotrexate level is < 0.05 micromolar.

5. Cancer Diagnosis Currently Being Treated With 5-Fluorouracil. (Note: Examples include hepatocellular carcinoma, ovarian cancer, gastric cancer, cervical cancer). Approve for 1 year if levoleucovorin is prescribed by or in consultation with an oncologist.

Dosing. Approve up to 100 mg/m² administered intravenously before each dose of 5-fluorouracil.¹

CONDITIONS NOT RECOMMENDED FOR APPROVAL
Levoeleucovorin has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions.

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

HISTORY
<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes*</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Policy</td>
<td>--</td>
<td>06/18/2019</td>
</tr>
</tbody>
</table>